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Abstract
PURPOSE—To testthe hypothesis that inflammation measured by white blood cell count (WBC)
and C-reactive protein (CRP) is associated positively with incident heart failure (HF).
METHODS—Using the Atherosclerosis Risk in Communities (ARIC) Study, we conducted
separate Cox proportional hazards regression analyses for WBC (measured 1987 to 1989) and
CRP (measured 1996 to 1998) in relation to subsequent heart failure occurrence. A total of 14,485
and 9,978 individuals were included in the WBC and CRP analyses, respectively.
RESULTS—There were 1647 participants that developed HF during follow up after WBC
assessment and 613 developed HF after CRP assessment. After adjustment for demographic
variables and traditional HF risk factors, the hazard ratio (95% CI)for incident HF across quintiles
of WBC was 1.0, 1.10 (0.9-1.34), 1.27(1.05-1.53), 1.44(1.19-1.74), and 1.62(1.34-1.96) (p trend
<0.001); hazard ratio across quintiles of CRP was 1.0, 1.03 (0.68-1.55), 0.99 (0.66-1.51), 1.40
(0.94-2.09) and 1.70 (1.14-2.53) (p trend 0.002). Granulocytes appeared to drive the relation
between WBCs and heart failure [hazard ratios across quintiles: 1.0, 0.93(0.76-1.15), 1.26
(1.04-1.53), 1.67(1.39-2.01) and 2.19 (1.83-2.61) (p trend <0.0001)], while lymphocytes or
monocytes were not related.
CONCLUSIONS—Greater levels of WBC (especially granulocytes) and CRP are associated with
increased risk of heart failure in middle-aged adults, independent of traditional risk factors.
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INTRODUCTION
Inflammation, as reflected by an elevated C-reactive protein (CRP) or white blood cell count
(WBC), is considered to be important in the development of coronary heart disease (CHD)
(1). A few population studies have suggested that higher CRP may also be associated with
increased risk of heart failure (4-9). In several studies this association was independent of
prevalent or incident CHD. CRP is associated positively with hypertension, obesity,
diabetes, smoking and inactivity and inflammation accompanying these conditions could
contribute to heart failure. While evidence for a link between CRP and heart failure is
growing, to our knowledge, no population study has examined the association of WBC in
men and women with incident heart failure. WBC and CRP may be implicated in the
development of heart failure by the immune system acting as a modulator of myocyte injury
(9) and inflammatory reactions contributing to the structural and functional deteriorations
observed in failing human hearts (10). Higher levels of inflammatory markers also have
been associated with increased severity, mortality and morbidity in patients with heart
failure (11-14).
We used data from the Atherosclerosis Risk in Communities (ARIC) Study, a cohort of
middle-aged adults, to test the hypotheses that CRP and WBC are associated positively with
incidence of heart failure.
METHODS
Study Population and Design
The Atherosclerosis Risk in Communities (ARIC) Study (15) is a prospective cohort study
of 15,792 men and women aged 45 to 64 years in 1987 to 1989 in four US communities:
Forsyth County, North Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota;
and Washington County, Maryland. The baseline visit (visit 1) included interviews,
laboratory measurements, and clinic examinations. Additional visits were conducted in 1990
to 1992 (visit 2), 1993 to 1995 (visit 3) and 1996 to 1998 (visit 4). This study was approved
by the institutional review board (IRB) of the University of Minnesota.
Baseline Variables and Data Collection
Family history of CHD was defined by a history of CHD (myocardial infarction, coronary
reperfusion procedure) or sudden death due to CHD in a sibling or parent. Technicians
measured resting, seated blood pressure 3 times with a random-zero sphygmomanometer
and the average of the second and third readings was used for analysis. Body mass index
was calculated as measured weight (kg)/height (m2). Technicians measured circumferences
of the waist (umbilical level) and hip (maximum buttocks) to the nearest centimeter, and
calculated the waist/hip ratio (WHR). Medication use was self-reported and verified by the
inspection of medication bottles. Physical activity was self-reported and quantified as a
sports activity index ranging from 1 (low) to 5 (high) (16).
Fasting blood samples were drawn, and plasma and serum were frozen at -70° until
analyzed. At baseline, following standard ARIC protocols, measurements of serum glucose,
serum creatinine, plasma total cholesterol, triglycerides and high density lipoprotein (HDL)
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cholesterol were performed, and low density lipoproteins (LDL) cholesterol levels were
computed (17). WBC count was determined by automated particle counters within 24 hours
after venipuncture in local hospital hematology laboratories. The reliability coefficient for
the WBC count measurement was greater than 0.96 (18). Hemoglobin was determined in the
same laboratories. Estimated GFR (eGFR) was calculated using the abbreviated
Modification of Diet in Renal Disease (MDRD) Study equation(19). Apart from WBC and
hemoglobin, all laboratory measurements were repeated at visit 4, when CRP was measured
using an immunonephelometric assay (Dade Behring, Newark, Delaware). The reliability
coefficient was 0.95 (20).
Hypertension was defined as DBP ≥ 90 mm Hg, SBP ≥140 mm Hg or use of
antihypertensive medication. Diabetes was defined as a fasting serum glucose level ≥126
mg/dl, non-fasting glucose level ≥200 mg/dl, report of a physician diagnosis of diabetes or
current use of diabetes medication. Prevalent CHD was defined by electrocardiographic
evidence of previous myocardial infarction, history of physician diagnosed myocardial
infarction, or previous coronary revascularizationprocedure (bypass, angioplasty). Prevalent
heart failure was defined by the reported current intake of heart failure medication at visit 1
or evidence of manifest heart failure with presence of specific cardiac and pulmonary
symptoms (21-23).
Assessment of Incident Heart Failure and CHD
Incident cardiovascular events through December 31, 2005 were identified through annual
telephone calls to ARIC cohort participants to identify all hospitalizations, through a review
of local hospital discharge indexes, and through retrieval of death certificates. Because the
response to telephone calls is still over 93 percent and supplemented by hospital
surveillance, event ascertainment is quite complete.Incident heart failure was defined by the
first hospitalization or a death certificate with a heart failure discharge code (ICD9 428 or
ICD10 I50). Incident CHD was defined by a definite or probable myocardial infarction,
coronary angioplasty or coronary artery bypass surgery.
Statistical Analysis
From the 15,792 ARIC participants, we made exclusions as shown in Figures 1 and 2.
Analyses were conducted using SAS version 9.2 (24), separately for visit 1 WBC and visit 4
CRP. The primary analyses had WBC and CRP modeled as quintiles. We determined the
relation of WBC and CRP quintiles with other demographic and health characteristics, some
of which may be confounders in the analysis, using χ2 tests or ANOVA. Heart failure hazard
ratios across quintiles of WBC and CRP and 95% confidence intervals were calculated using
Cox-proportional hazards models. The proportionality assumption of all Cox models was
assessed by inspecting the log (-log [survival function]) curves. Trends in the hazards across
WBC and CRP quintiles were assessed by assigning equally spaced scores to the quintiles
and treating this as a continuous variable in the regression models (25).Analyses were also
conducted treating biomarkers as continuous variables or dichotomous variables above or
below the 90th percentiles for WBC and <1, 1-3 and ≥3 mg/L for CRPWe also evaluated the
relation of WBC subtypes (i.e. granulocytes, lymphocytes, and monocytes) to heart failure
risk. Follow up time began at entry into the study (visit 1for WBC, visit 4 for CRP) and
went to the first heart failure hospitalization, death, leaving the study, or else December 31,
2005.
Regression models first adjusted for demographics, including age (continuous), race (black,
white), gender, educational level (less than high school, high school or vocational training,
college or advanced degree) and ARIC field center. The second multivariate model adjusted
additionally for continuous BMI and WHR, smoking status (current, former, never), and
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sports activity index (scale 1 to 5). In the third model we evaluated whether the observed
WBC and CRP associations were independent of established heart failure risk factors by
further adjusting for hypertension, diabetes, prevalent CHD, family history of CHD,
medication use (antihyperlipidemic, digitalis, beta-blocker), and continuous LDL
cholesterol, HDL cholesterol, triglycerides, hemoglobin and eGFR. For all models, level of
significance was taken as p <0.05. Interactions were evaluated by including cross-product
terms in the models.
Using life test procedures, we also created survival curves for the proportion of individuals
who remained free of incident heart failure, stratified by WBC and CRP quintiles.
RESULTS
Baseline Characteristics
14,485 participants were included in the WBC (visit 1) analyses, and 9,978 were included in
the CRP (visit 4) analyses. At baseline, the mean WBC (SD) was 6.09 (1.86) × 109/L. The
mean age of the cohort was 54 years; 74% were white, 54% were female and 36% had more
than a high school education. As Table 1 shows, participants with higher WBC levels were
more often male, had higher levels of most heart failure risk factors, and as expected, were
more often white than black (18).
For visit 4, the mean CRP (SD) was 4.04 (4.86) mg/L. The mean age of participants at visit
4 was 63 years. Associations of covariates with CRP were similar to those for WBC except
that participants with higher CRP levels were more likely to be African American and
female (Table 2).
Outcomes
For the WBC analyses, participants were followed for a mean (SD) of 15.5 (4.0) years, and
1647 participants developed heart failure (74/10,000 person-years). Mean (SD) follow up
time for CRP analyses was 7.9 (1.7) years and 613 participants developed heart failure
(77/10,000 person-years). Life test survival analysis (figures 3 and 4) demonstrated that
higher levels of WBC and CRP were each risk factors for heart failure (log-rank χ2=241, p
<0.0001 and χ2=104, p<0.0001 respectively).
As shown in Table 3, crude hazard ratios (95% CIs) across quintiles of WBC were 1.0, 1.19
(0.98-1.44), 1.59 (1.33-1.91), 2.28 (1.91-2.71), and 2.81 (2.37-3.31) (p trend <0.0001).
There was some attenuation of this association after adjustment for potential confounders
(Models 2 and 3, Table 3), but a moderate positive association between WBC and heart
failure remained. When WBC was modeled as a continuous variable, the hazard ratio (95%
CI) for a 1 standard deviation (1.86 × 109/L) increase in WBC was 1.17(1.12-1.24), in
Model 3. A significant positive association between WBC and incident heart failure still
remained when WBC was modeled as high (>9.0 × 109/L) vs. low (≤9.0 × 109/L); the
hazard ratio (95% CI) was 1.28(1.08-1.51). When CHD was included as a time-dependent
covariate, the results obtained were not substantially different from when only prevalent
CHD at baseline was used(HR (95% CIs) for WBC quintiles adjusted for Model 3 covariates
and CHD as a time-dependent covariate: 1.00, 1.10 (0.90-1.34), 1.24 (1.03-1.50), 1.41
(1.17-1.70), 1.54 (1.27-1.86); p-trend <0.0001).
Differentiating WBC count showed a strong positive association between granulocytes
(neutrophils, eosinophils and basophils) both individually and when assessed collectively,
and heart failure incidence. There was no association between lymphocytes or monocytes
and incident heart failure. After adjustment for potential confounders (Model 3), the hazard
ratios (95% CIs) across quintiles of granulocytes were 1.0, 0.93 (0.76-1.15), 1.26
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(1.04-1.53), 1.67 (1.39-2.01) and 2.19 (1.83-2.61) (p trend <0.0001). Hazard ratios across
quintiles of lymphocytes and monocytes were 1.0, 0.93, 0.93, 0.95, 0.86 (p trend=0.20) and
1.0, 0.94, 0.94, 0.95, 0.89 (p trend=0.19) respectively.
CRP quintiles were strongly associated with heart failure incidence. Crude hazard ratios
(95% CIs) were 1.0, 1.15(0.85-1.56), 1.34 (0.99-1.80), 1.79 (1.36-2.37) and 2.86 (2.20-3.72)
(p trend <0.0001). After adjustment for potential confounders (Model 3, Table 4), there still
was a moderate positive association between CRP and incident heart failure. Hazard
ratios(95% CIs)across the quintiles were 1.0, 1.03 (0.68-1.55), 0.99 (0.66-1.51), 1.40
(0.94-2.09) and 1.70 (1.14-2.53) (p trend 0.002), suggesting CRP was associated with heart
failure mostly above 3.2 mg/L. When we modeled CRP as a continuous variable, the hazard
ratio (95% CIs) for a 1 standard deviation (4.86 mg/L) increase in CRP was 1.16(1.05, 1.28)
in Model 3 covariates. The hazard ratios (95% CIs) were1.00, 0.97 (0.74-1.27), 1.41
(1.09-1.82) for CRP levels <1, 1-3 and ≥3 mg/L respectively. P=0.0009.. Modeling CHD as
a time-dependent variable did not change the results(HR (95% CIs) for CRP quintiles
adjusted for Model 3 and CHD as a time-dependent covariate: 1.00, 0.91 (0.67-1.25), 0.87
(0.64-1.19), 1.19 (0.88-1.62), 1.54 (1.15-2.07); p-trend <0.0001).For the WBC analyses,
there were 1620 incident CHD events that preceded HF and for the CRP analyses, 252
incident CHD events preceded HF.
There was no interaction of race, gender, or prevalent CHD with WBC or CRP in incident
heart failure. There was a weak interaction of hypertension status with WBC (p = 0.04) but
not with CRP. The hazard ratios(95% CIs) for WBC quintiles 1 to 5 were 1.0, 1.20
(0.90-1.56), 1.27 (0.99-1.63), 1.41 (1.09-1.82) and 1.49 (1.16-193) in participants with
prevalent hypertension and 1.0, 0.96(0.71-1.30), 1.24 (0.93-1.65), 1.48 (1.12-1.97) and
1.77(1.34-2.35) in normotensive participants. There was no evidence of an interaction
between WBC and CRP levels on risk of incident HF (pInteraction = 0.97).When we evaluated
the relation of baseline WBC to incident HF after adjusting for visit 4 CRP, the results were
only slightly attenuated, and a significant association persisted between WBC and incident
HF after CRP adjustment (p = 0.002).
CONCLUSIONS
In this analysis of a prospective, community-based, biracial sample of middle-aged adults,
higher blood levels of WBC and CRP were strongly associated with increased incidence of
heart failure. After adjustment for traditional risk factors, the associations were weakened
but moderate positive associations still remained. These findings are consistent with
previously published studies of the relationship between CRP and heart failure (4-8, 26).
The present study extends previous findings to show that elevated WBC (particularly
granulocytes) and CRP are associated with heart failure independent of CHD, race or gender
in the general middle-age population.
WBC
Although elevated WBC has consistently been an independent risk factor for future
cardiovascular outcomes (3), to our knowledge, our study is the first population based study
to demonstrate that elevated WBC is an independent risk factor for incident heart failure in
both men and women. Also, to our knowledge, this is the first study to show that the
association exists and is similar when adjusted for CHD as a time-varying covariate. One
population based study (27) investigating the association between WBC and incidence of
hospitalizations due to heart failure in men without prior history of MI, observed HR of 1.0,
1.26, 1.24 and 1.73 across quartiles of WBC. Two other studies conducted in acute
myocardial infarction patients with reduced ejection fraction reached similar conclusions. In
the Studies of Left Ventricular Dysfunction (SOLVD) among CHD patients with reduced
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ejection fraction (28), a WBC count of > 7000/mm3 (compared with WBC ≤ 7000/mm3)
was associated with a greater likelihood and increased severity of heart failure. In a
prospective analysis of the Thrombolysis In Myocardial Infarction (TIMI) trials (29), even
after controlling for numerous confounders, the WBC count remained independently
associated with the development of new heart failure in patients with acute myocardial
infarction. Although some studies have suggested that WBC may increase as a result of the
low cardiac output situation in heart failure (10, 30), our results show that elevated WBC,
probably reflecting greater systemic inflammation, may be etiologically relevant for heart
failure. The strength of the association after adjustment for heart failure risk factors (about
67% increased risk in the highest quintile vs. the lowest quintile), the presence of a stepwise
rise in heart failure risk across increasing quintiles of WBC, the demonstration of a temporal
sequence, and the consistency of results in multiple analyses all support this notion
(reviewed in Table 5). In the ARICdata, the increased risk for heart failure associated with
increased WBC count was driven by granulocytes (neutrophils, basophils, eosinophils).
Consistent with our findings, previous studies (31, 32) have suggested that higher neutrophil
or granulocyte counts may be stronger predictors of CHD than other WBC components. A
recent Mayo Clinic study (33) also found a positive association between neutrophil count
and incident HF in patients with MI; however, mechanisms explaining this occurrence
remain unclear.The hazard ratios of HF by WBC quintiles in non-hypertensives were higher
and more pronounced than the hazard ratios in hypertensives. This was not hypothesized a
priori, could be due to chance, and would requirereplication before it should be considered
biologically real. However, we find it logicalthat in the absence of hypertension, a major risk
factor for HF, inflammation would be a more potent HF risk factor.
CRP
Compared with patients in the lowest quintile of CRP, the adjusted hazard for heart failure
was increased 1.7 fold in the highest CRP quintile (Table 4). Individuals in the second and
third CRP quintiles did not seem to have a significantly increased risk for heart failure
implying that only relatively high levels of CRP are associated with increased heart failure
risk. Various studies have found a positive association between CRP and heart failure (4-8)
(reviewed in Table 6). For example, investigators of the Cardiovascular Health Study(34)
observed a RR of 1.93 for incident heart failure in elderly individuals with CRP >7.0mg/L
(vs. ≤7.0mg/L).
Mechanisms
The development and progression of heart failure is multi-factorial and there is growing
evidence that systemic inflammation (indicated by elevated WBC and CRP) may be
mechanistically involved by contributing to myocardial dysfunction and other aspects of
advanced heart failure including weight loss, anemia and endothelial dysfunction (35, 36).
Oxidative stress and proinflamatory cytokines released by white blood cells are associated
with myocyte dysfunction and pulmonary edema (35, 37). In addition, elevated WBC can
lead to abnormal leukocyte aggregation, vessel obstruction, endothelial injury and decreased
perfusion in heart muscle, leading to CHD which can predispose to heart failure (3).
Furthermore, just as in other chronic inflammatory conditions, granulocyte colony-
stimulating factor(G-CSF) and other pro-inflammatory cytokines may cause granulocytes to
live longer in individuals with clinical and subclinical HF, and thus enhance their function as
effector cells of the inflammatory process in these individuals (38). Other studies in both
animal and human models have however proposed that G-CSF may improve outcomes in
heart failure of ischemic etiology (39).In addition, CRP may activate the complement
system, stimulate cytokine production, cause myocyte loss and promote cardiac dysfunction
which leads to heart failure (40). Adjusting for CHD as a time-varying covariate had little
impact on our results. The motivation of this analysis was to gauge whether our findings that
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inflammation was associated with a greater risk of HF were simply due to the fact that
inflammation is associated with a greater risk of CHD, and CHD is associated with a greater
risk of HF. The fact that our results were similar after more carefully accounting for CHD by
using incident CHD as a time-varying covariate suggests that inflammation may be
associated with risk of HF at least partly independently of CHD.
Study Limitations
One limitation, as in all observational studies, is potential residual confounding. Second, it is
theoretically possible that subclinical heart failure may have caused an increase in WBC and
CRP levels, rather than increased levels of WBC and CRP having predisposed to heart
failure. However, there was a long follow-up between the baseline evaluation and incident
events (mean follow-up time of 15.5 and 7.9 years respectively for eventual cases of
incident HF).Third, we had single measures of WBC and CRP, which may theoretically lead
to some misclassification of exposure, but short-term reliability of WBC and CRP was high
and so there is probably little bias. It is unlikely that an acute inflammatory response would
have impacted our results much, as we excluded individuals with extreme values from our
analyses.One of our criteria for prevalent HF was reported use of HF medications. Some HF
medications are also commonly used in treatment of hypertension and CHD, but we required
the participant report medication was used for HF to meet this prevalent HF criterion. In any
case, there should be little impact of misclassification bias on hazards ratios, because all
these individuals with presumed baseline HF were excluded from the analysis. Furthermore,
some studies have found other markers, like brain natriuretic peptide and urinary
albumin:creatinine, ratio to be associated with incident HF. We did not have other
biomarkers at similar time periods to compare with WBC and CRP. Finally, WBC and CRP
were measured many years apart, thus assessment of independent or joint associations of
these markers with heart failure incidencemay yield biased results.
We found that elevated WBC (especially granulocytes) and CRP appear to be risk factors
for incident heart failure, independent of traditional risk factors. Further studies designed to
investigate the role of these inflammatory markers in heart failure are needed to determine
whether this is indeed a causal relation and whether measuring these markers may be helpful
in prediction and prevention of heart failure.
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Inclusion and exclusion criteria for WBC Visit 1 analysis
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Inclusion and exclusion criteria for CRP Visit 4 analysis
Bekwelem et al. Page 12














Life-test estimates of survival function. Proportion of participants free of heart failure by
WBC quintiles, ARIC 1987-2005
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Life-test estimates of survival function. Proportion of participants free of heart failure by
CRP quintiles, ARIC 1996-2005
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TABLE 5
Summary of existing studies on white blood cell count (WBC) and heart failure




TIMI: 975 MI patients; 64 incident HF
events
OR of HF = NA, 0.11, 0.24, 1.00 per quartile of WBC (ref
was highest quartile), multiply-adjusted
Engström (27) Cohort 16,940 Swedish men; 436
hospitalizations for HF
HR of HF = 1.00, 1.26, 1.24, 1.73 (p<0.0001) per quartile of
WBC, multiply-adjusted
Dragu (41) Cohort 1037 MI patients; unknown number of
rehospitalizations for HF
HR of HF 1.6 (p=0.015) in upper quartile of neutrophils
compared to lower three quartiles, multiply-adjusted. No
association for other WBC components
This study Cohort ARIC: 14,485 middle aged adults; 1,647
incident HF events
HR of HF = 1.00, 1.10, 1.29, 1.46, 1.67 (p<0.0001) per
quintile of WBC, multiply-adjusted.
ARIC = Atherosclerosis Risk in Communities Study; HF = heart failure cases; HR = hazard ratio; MI = Myocardial infarction; NA = no one in the
lowest quartile of WBC had heart failure, so these patients were dropped from the model; OR = odds ratio; TIMI =Thrombolysis In Myocardial
Infarction 10 Study; WBC = white blood cell count.
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TABLE 6
Summary of existing studies on C-reactive protein (CRP) and heart failure
Author Design Sample Association
Gottdiener (5) Cohort CHS: 5,888 Elderly individuals
>65years; 597 incident HF events
HR of HF = 1.0, 0.95, 1.01, 1.27, 1.91(p<0.0001) per quintile of CRP,
multiply-adjusted
Vasan (6) Cohort Framingham: 732 Elderly men &
women; 56 incident HF events
HR of HF = 2.81 (1.22-6.50) (p=0.02) for CRP ≥5 mg/dL vs. <5mg/dL,
multiply-adjusted
Cesari (7) Cohort Health ABC: 2225 individuals 70-79
years; 92 incident HF events
HR of HF = 1.0, 1.43, 2.60 (p<0.001) per tertile of CRP, multiply-
adjusted
Kardys (8) Cohort Rotterdam: 6,437 individuals
≥55years; 551 incident HF events
HR of HF = 1.0, 1.14, 1.17, 1.71 (p<0.001) per quartile of CRP, multiply-
adjusted. Association stronger in men than women
Bahrami (9) Cohort MESA: 6,814 individuals 45-84 years;
79 incident HF events
HR of HF = 1.38 (1.01-1.86) per 1 SD CRP increment, multiply-adjusted
This study Cohort ARIC: 9,978 middle aged adults; 613
incident HF events
HR of HF = 1.27 (1.07-1.87) for CRP >11.5 mg/L vs. ≤11.5 mg/L,
multiply-adjusted
HR of HF = 1.16 (1.05-1.28) per 1 SD CRP increment, multiply-adjusted
HR of HF = 1.00, 1.03, 0.99, 1.40, 1.70 (p=0.002) per quintile of CRP,
multiply-adjusted
ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; CRP = C-reactive protein; Framingham = the
Framingham Heart Study; Health ABC =the Health, Aging, and Body Composition Study; HF = heart failure cases; HR = hazard ratio; MESA =
Multi-Ethnic Study of Atherosclerosis; MI = myocardial infarction; NA = no one in the lowest quartile of WBC had heart failure, so these patients
were dropped from the model; Rotterdam = the Rotterdam Study; SD = standard deviation; WBC = white blood cell count.
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